Physician profile
John Hines
NPI 1629031950
$3,420.23
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2020: $629 · 2021: $517 · 2022: $756 · 2023: $143 · 2024: $31.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $459.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $442.28 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $289.94 | 2019-2022 | |
| Amgen INC. | $289.58 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $275.57 | 2019-2023 | Breztri |
| Abbvie INC. | $227.21 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $226.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $163.02 | 2019-2021 | |
| Lilly USA, LLC | $162.93 | 2019-2022 | |
| Pfizer INC. | $130.95 | 2019-2020 | |
| Astellas Pharma US INC | $129.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $112.13 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.57 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $59.23 | 2022-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $47.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.96 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $37.20 | 2019 | |
| Idorsia Pharmaceuticals US INC | $28.36 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $14.77 | 2019 | |
| Eisai INC. | $12.92 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.14 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.